Helen Innes

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 283 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study

Helen Innes, David B. Smith, S.M. O'Reilly et al. · British Journal of Cancer · 2003 · 138 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients

Helen Innes, Dun Liu, Roger Barraclough et al. · British Journal of Cancer · 2006 · 135 citations · Full text

Medicine, Oncology, Pathology +17

Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice

Helen Innes, Sheow Lei Lim, Allison Hall et al. · Supportive Care in Cancer · 2007 · 84 citations

Medicine, Oncology, Chemotherapy +14

Disinformation and digital influencing after terrorism: spoofing, truthing and social proofing

Martin Innes, Diyana Dobreva, Helen Innes · Contemporary Social Science · 2019 · 55 citations

Public Affairs, Communication, Political Communication +16